coadministered cagrilintide and semaglutide in adults with overweight or obesity Efficacy safety of co-administered once-weekly 2·4 mg once-weekly 2·4 mg type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial cagrilintide protocol Once-weekly for weight

Nutrition Facts / Valeur nutritive Additional Ingredients Allergy Information Warnings

Mitra S, Behbahani H, Eriksdotter M

Participants completed a baseline survey, a 28-day diary, and a study completion survey through a custom app interface

Getting back on schedule quickly prevents the disruptions that turn a one-week vacation into a month-long protocol setback

the outcome measures must include the live-birth rate or clinical pregnancy rate

However, persistent severe nausea lasting beyond two weeks, vomiting, or inability to keep fluids down warrants immediate contact with your healthcare provider to rule out other causes and discuss dose adjustments